Classification of Amyloidosis by Mass Spectrometry-Based Proteomics
The developments in mass spectrometry-based proteomic technologies have created unprecedented opportunities for identification of proteins in routine clinical biopsy specimens. The application of the technology to classification of amyloidosis has resulted in the first clinical application of shotgun proteomics. In the context of amyloid classification, mass spectrometry-based proteomic assays offer many advantages over immunoassay-based methods and clinical surrogates. The method is readily applicable to FFPE or fresh/frozen routine clinical biopsy specimens and requires very little tissue. Unlike immunoassays which require good reagents for each target, LC–MS/MS can detect all amyloidogenic proteins in a single analysis. Given these analytical and operational advantages, and the far superior specificity and sensitivity offered by laser microdissection (LMD) and LC–MS/MS based methods, LMD- and LC–MS/MS-based analysis is now considered the gold standard for classification of amyloidosis.
KeywordsAmyloidosis Classification Mass spectrometry Proteomics Microdissection Amyloid typing
- 26.Lacy MQ, Theis JD, Vrana JA, et al. Lysozyme amyloidosis (ALys) affecting a family with a new variant of lysozyme gene (LYZ) and hereditary haemorrhagic telangiectasia. Amyloid. 2010;17:125.Google Scholar